Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Cancer Res. 2016 Mar 15;76(6):1578–1590. doi: 10.1158/0008-5472.CAN-15-2524

Figure 7. The enhanced anti-tumor effect offered by PD1CD28 is dependent on CD28 signaling induced by PDL1 binding.

Figure 7

T-cells retrovirally transduced with either PSCA-BBz alone, PSCA-BBz with PD1CD28 switch-receptor (PSCA-BBz/PD1CD28), or PSCA-BBz together with mutated PD1CD28 switch-receptor in which the CD28 signaling transduction proximal YMNM motif and distal proline-rich motifs PRRP and PYAP were mutated to FFFF, ARRA and AYAA respectively (PSCA-BBz/PD1CD28m) were tested in PC3-PSCA-PDL1 tumor engrafted NSG mice. Mice (n=5) were implanted in the flanks with PC3-PSCA-PD-L1 tumor cells (1×106 cells/mouse, s.c.) and were treated with T-cells (IV) at day 23 after tumor inoculation. T-cells were given as a single injection of 2×106/mouse. Injection of mock T-cells served as control. Tumor sizes were measured and the tumor volume was calculated and plotted (A & B). The percentage survival per group was determined on a daily basis and is represented in a Kaplan-Meier survival curve (C).